Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 971 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disruptive Behavior Disorders Clear all
Completed Not applicable Interventional

Preference and Goal Directed Attention Deficit Hyperactivity Disorder Care- Pilot Study

NCT01487967
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Preference and Goal Instrument
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD

NCT00500071
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Vyvanse (lisdexamfetamine dimesylate)
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
46
States / cities
Scottsdale, Arizona • El Centro, California • Rolling Hills Estates, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 22, 2026, 5:59 AM EDT
Recruiting No phase listed Observational

Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool

NCT07764536
View directory record Official record
Conditions
Disruptive Behavior Disorders, Conduct Disorder, Oppositional Defiant Disorder, Attention-deficit/Hyperactivity Disorder
Interventions
Psychotherapy
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 13 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study for Naltrexone on the Abuse Potential of Methylphenidate

NCT03769064
View directory record Official record
Conditions
Naltrexone, Methylphenidate Abuse
Interventions
Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421
Drug
Lead sponsor
Avekshan LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 22, 2026, 5:59 AM EDT
Recruiting Not applicable Interventional

Executive Function and Parenting in Childhood

NCT06241300
View directory record Official record
Conditions
Disruptive Behavior Disorder, Childhood Onset, Disruptive Behavior, Executive Function
Interventions
Chicago Parent Program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
4 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00556959
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
high dose clonidine HCl sustained release, low dose clonidine HCl sustained release, placebo
Drug
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Gainesville, Florida • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Milk Thistle in Trichotillomania in Children and Adults

NCT02473913
View directory record Official record
Conditions
Trichotillomania, Hair Pulling Disorder
Interventions
Milk Thistle, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
10 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Investigating the Effect of Vortioxetine in Adult ADHD Patients

NCT02327013
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Beverly Hills, California • Garden Grove, California • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01364662
View directory record Official record
Conditions
Impulsive Aggression Comorbid With ADHD
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 22, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pimavanserin and Aggression and Social Cognition.

NCT05895513
View directory record Official record
Conditions
Intermittent Explosive Disorder
Interventions
Pimavanserin 34 mg, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Early Phase 1 Interventional

Oxytocin and Cognitive Control in Adult ADHD

NCT03136263
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Oxytocin nasal spray, Placebo nasal spray
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Lab School Day Study for CONCERTA of Older Children With ADHD

NCT00799409
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo/ CONCERTA (methylphenidate HCl), CONCERTA (methylphenidate HCl) / Placebo
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
9 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Irvine, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

dHealth Solution for Improving Parent Adherence to Behavioral Treatment for ADHD

NCT04025814
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CaregiverAssist, Behavioral Parent Training (CLS Parent Group)
Device · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Dasotraline Pediatric Extension Study

NCT02457819
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Dothan, Alabama • Culver City, California • Wildomar, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 22, 2026, 5:59 AM EDT
Not listed Not applicable Interventional

Mindfulness Intervention for College Students With ADHD

NCT06076967
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mindfulness Awareness Practices for ADHD (adapted), Services-As-Usual
Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
17 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tuscaloosa, Alabama • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 22, 2026, 5:59 AM EDT
Enrolling by invitation No phase listed Observational

Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models

NCT06792175
View directory record Official record
Conditions
Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD), Attention Deficit Hyperactivity Disorder (ADHD), Schizophrenia Spectrum &Amp; Other Psychotic Disorders, Post Traumatic Stress Disorder, Obsessive Compulsive Disorder (OCD)
Interventions
Solicue Machine Learning Models, Mercuria Machine Learning Models
Diagnostic Test
Lead sponsor
Psyrin Inc.
Industry
Eligibility
13 Years to 60 Years
Enrollment
500 participants
Timeline
2025 – 2026
U.S. locations
2
States / cities
Brookline, Massachusetts • Zanesville, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders

NCT00402857
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Interventions
Incredible Years Program
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
22 Months to 38 Months
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
9
States / cities
Chelsea, Massachusetts • Dorchester, Massachusetts • Jamaica Plain, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

NCT00663442
View directory record Official record
Conditions
ADHD
Interventions
OROS methylphenidate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
6 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Effects of LDX on Functioning of College Students With ADHD

NCT01342445
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
lisdexamfetamine dimesylate, Placebo
Drug
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 28 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bethlehem, Pennsylvania • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory

NCT00530257
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, OROS-methylphenidate
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Developmental Origins of Attention Deficit Hyperactivity Disorder

NCT01982422
View directory record Official record
Conditions
Inattention, Impulsivity, Anxiety
Interventions
Whole Food, Nutrient-Dense Dietary Intervention, Standard of Care
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

NCT00585910
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine and OROS Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 22, 2026, 5:59 AM EDT
Withdrawn Phase 4 Interventional

Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD

NCT06077669
View directory record Official record
Conditions
ADHD
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)

NCT01070394
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LDX Treatment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 22, 2026, 5:59 AM EDT